Clinical Trials at Virginia Cancer Specialists
As of August 2026, 66 paid clinical trials are recruiting at Virginia Cancer Specialists, located at 8613 LEE HWY # 200N, FAIRFAX, VA 22031-2171, phone (703) 280-5390 in Fairfax, Virginia. Active studies at this site cover conditions such as Advanced Solid Tumor, Ovarian Cancer and Endometrial Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Fairfax
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
67 clinical trials at Virginia Cancer Specialists
·Clear filters·A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Common conditions studied in Fairfax
- Advanced Solid Tumor (33 active studies)
- Ovarian Cancer (28 active studies)
- Endometrial Cancer (26 active studies)
- Advanced Solid Tumors (25 active studies)
- Breast Cancer (23 active studies)
- Colorectal Cancer (21 active studies)
Leading research sponsors in Fairfax
- AstraZeneca
- AbbVie
- Merck Sharp & Dohme LLC
- Eli Lilly and Company
- Janssen Research & Development, LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Fairfax?
There are approximately 492 recruiting clinical trials in Fairfax, Virginia listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Fairfax pay participants?
Most recruiting trials in Fairfax compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Fairfax?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Fairfax?
The most common conditions under active study in Fairfax include Advanced Solid Tumor (33), Ovarian Cancer (28), Endometrial Cancer (26), Advanced Solid Tumors (25), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Fairfax?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Fairfax on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Fairfax?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Fairfax?
Recruiting research sites in Fairfax include NEXT Virginia, Virginia Cancer Specialists, Inova Schar Cancer Institute, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Fairfax right now?
The largest active categories in Fairfax are Cancer & tumors (333), Cardiovascular (8), Neurology & pain (4). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Virginia Cancer Specialists?
Virginia Cancer Specialists is located at 8613 LEE HWY # 200N, FAIRFAX, VA 22031-2171. Use the Google Maps link in the intro above to get directions.
How do I contact Virginia Cancer Specialists?
You can reach Virginia Cancer Specialists by phone at (703) 280-5390. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.